11 december 2005: Bron: Oncolytics

Een kleine preklinische studie geeft veelbelovende resultaten voor het gebruik van een virusinjectie intraveneus (Reolysin) bij kankerpatiënten met solide tumoren. We weten dat Reolysin al goede resultaten laat zien in lopende studies bij o.a. hersentumoren en prostaatkanker. Hier een kort artikel over deze nieuwe studieresultaten. Let wel dit zijn hele kleine studies en bekijk ze kritisch, desalniettemin wel hoopgevend want injecteren met een virus lijkt toch een hoopvolle benadering. Zie ook Newcastlevirus informatie

PRNewswire: Reovirus Destroys Cancer (M/Calgary)

Reovirus Seeks Out and Destroys Cancer Cells, Preliminary Study Results Show

CALGARY, Alberta, Dec. 5 /PRNewswire/ -- For the first time, researchers ave demonstrated that the reovirus, a naturally occurring virus found in the environment, can seek out and destroy cancer cells in a variety of tumor types and locations when delivered intravenously to patients.

Preliminary results from an ongoing patient study in the United Kingdom have demonstrated that Reolysin was well-tolerated by patients and there was vidence of virus replication within several types of tumors in patients who had failed all previous treatments. Of 12 patients who received doses of Reolysin on five consecutive days, at least four patients had stabilization of the measured tumor. Patients who experienced tumor activity included those with colorectal, prostate, non-small-cell lung and bladder cancers.

These early results, presented by Dr. Johann S. de Bono of the Royal Marsden Hospital in London at the most recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, showed that the reovirus, when delivered intravenously, enters cancer cells, replicates within them and ultimately kills them. It works by replicating within cancer cells that have an activated Ras pathway, a common mutation that is shared by approximately two thirds of all human cancers.

We believe that these early results are the most encouraging data we have seen to date in our work with Reolysin; says Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc., the company sponsoring the study. Oncolytics has also started patient enrolment in a similar intravenous trial in the United States at the Montefiore Medical Center in New York City. This clinical trial is an open-label, dose- escalation Phase I study in which a single dose of Reolysin is administered intravenously to patients with advanced and/or metastatic solid tumors.


For Canada:
Oncolytics Biotech Inc.
Brad Thompson
210, 1167 Kensington Cr NW
Calgary, Alberta T2N 1X7
Tel: 403.670.7377
Fax: 403.283.0858

For Canada:
The Equicom Group Inc.
Joanna Longo
20 Toronto Street
Toronto, Ontario M5C 2B8
Tel: 416.815.0700 ext. 233
Fax: 416.815.0080

For United States:
The Investor Relations Group
Gino De Jesus or Dian Griesel, Ph.D.
50 Pine Street, 6th Floor
New York, NY 10005
Tel: 212.825.3210
Fax: 212.825.3229

Plaats een reactie ...

Reageer op "Virusinjectie (REOLYSIN) geeft in fase I studie veelbelovende resultaten bij kankerpatiënten met solide tumoren Artikel geplaatst december 2005"

Gerelateerde artikelen

Gerelateerde artikelen

Virusinjectie (REOLYSIN) geeft >> REOLYSIN: Virusinjectie geeft >> REOLYSIN virus ingezet als >> Reolysin, een overzicht van >>